Related Experiment Videos
Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with
1Channing Laboratory Brigham and Women's Hospital, Harvard Medical School Boston, Massachusetts 02115, USA.
Abstract:
The emergence of multiple antibiotic-resistant microorganisms has led to a search for alternatives to traditional therapeutic regimens. PGG glucan is a soluble beta-glucan immunomodulator that selectively enhances the microbicidal activities of neutrophils and macrophages without stimulating proinflammatory cytokine production. In the present studies, we examined the ability of PGG glucan to act in concert with antibiotics to decrease mortality in a rat model of intraabdominal sepsis using antibiotic-resistant bacteria as infectious inocula. Results of these studies demonstrated that prophylaxis with PGG glucan in combination with antibiotics provided enhanced protection against lethal challenge with Esherichia coli or Staphylococcus aureus as compared with the use of antibiotics alone.
Insights
PGG glucan, a beta-glucan immunomodulator, enhances antibiotic effectiveness against resistant bacteria. Combining PGG glucan with antibiotics significantly reduced mortality in a rat sepsis model.
Area of Science:
- Immunology
- Pharmacology
- Microbiology
Background:
- Rising antibiotic resistance necessitates novel therapeutic strategies.
- PGG glucan is an immunomodulator enhancing innate immune cell activity.
- It selectively boosts neutrophil and macrophage microbicidal functions without inducing inflammation.
Purpose of the Study:
- To investigate the synergistic effect of PGG glucan and antibiotics in treating intraabdominal sepsis.
- To evaluate the efficacy of this combination against antibiotic-resistant bacterial infections in a rat model.
Main Methods:
- A rat model of intraabdominal sepsis was established using antibiotic-resistant Escherichia coli and Staphylococcus aureus.
- Animals received prophylaxis with PGG glucan in combination with standard antibiotics.
- Mortality rates were compared between combination therapy and antibiotic-only groups.
Main Results:
- Prophylaxis with PGG glucan and antibiotics demonstrated significantly enhanced protection against lethal bacterial challenge.
- The combination therapy markedly decreased mortality compared to antibiotics administered alone.
- PGG glucan potentiated the therapeutic effect of antibiotics against resistant pathogens.
Conclusions:
- PGG glucan can be effectively combined with antibiotics to improve treatment outcomes for sepsis caused by resistant bacteria.
- This combination therapy represents a promising approach to combatting infections from multidrug-resistant microorganisms.
- Further research into PGG glucan's role in antimicrobial strategies is warranted.